Rapid Regression of Advanced Hepatocellular Carcinoma Associated with Elevation of Des-Gamma-Carboxy Prothrombin after Short-Term Treatment with Sorafenib – A Report of Two Cases

BACKGROUND: Sorafenib is the first molecular-targeted agent that is effective for advanced hepatocellular carcinoma (HCC), with prolongation of survival. However, a complete response is very rare, and rapid regression of HCC after short-term treatment with sorafenib has not been reported previously....

Descripción completa

Detalles Bibliográficos
Autores principales: Nakazawa, Takahide, Hidaka, Hisashi, Shibuya, Akitaka, Koizumi, Wasaburo
Formato: Texto
Lenguaje:English
Publicado: S. Karger AG 2010
Materias:
Published: August 2010
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3042023/
https://www.ncbi.nlm.nih.gov/pubmed/21347197
http://dx.doi.org/10.1159/000319831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3042023/
https://www.ncbi.nlm.nih.gov/pubmed/21347197
http://dx.doi.org/10.1159/000319831

Ejemplares similares